Merck & Co., Inc. Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31)
Merck & Co., Inc. (MRK) had Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) of $32.00 million as of 2011-03-31, per its 10-Q filed 2011-05-09.
Discontinued › Notes › Derivative Instruments and Hedging Activities
us-gaap:DerivativeAssetNotDesignatedAsHedgingInstrumentFairValue · last filed 2011-05-09
- 2011-03-31: Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $32.00M.
- 2010-12-31: Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $95.00M.
- 2010-09-30: Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $54.90M.
- 2010-06-30: Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $192.00M.
| Period end | Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) | Derivative Asset Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) as first filed |
|---|---|---|
| 2011-03-31 | $32.00M 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $95.00M 10-Q · filed 2011-05-09 | |
| 2010-09-30 | $54.90M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $192.00M 10-Q · filed 2010-08-06 | |
| 2009-12-31 | $60.00M 10-K · filed 2011-02-28 | $60.30M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |